ABVC Biopharma Inc (ABVC) FinancialsABVCABVC Biopharma Inc

Evaluating the bottom line, ABVC Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -82.15%, provide a clear picture of how effectively ABVC converts its operational activities into shareholder value.

In the context of the broader market, ABVC competes directly with industry leaders such as CPHI and BYSI. With a market capitalization of $26.16M, it holds a leading position in the sector. When comparing efficiency, ABVC's gross margin of N/A stands against CPHI's 8.81% and BYSI's N/A. Such benchmarking helps identify whether ABVC Biopharma Inc is trading at a premium or discount relative to its financial performance.

ABVC Biopharma reported a significant increase in total assets by 103% year-over-year, reaching $16.2 million, but has not generated any revenue for several quarters. The company has also reported substantial net losses, including -$3.56 million in Q4 2025, which raises concerns about its financial sustainability.